Importance Sodium-glucose cotransporter 2 inhibitors are known to reduce heart failure
events and slow progression of kidney disease among patients with heart failure and a …

Background: Many patients with heart failure and reduced ejection fraction (HFrEF) have
chronic kidney disease that complicates pharmacological management and is associated …

Aims Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular
death among patients with heart failure with mildly reduced or preserved ejection fraction. In …

Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a
range of morbidity and mortality outcomes in patients with heart failure regardless of ejection …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure and cardiovascular death among patients with chronic heart …

Importance Dapagliflozin was recently shown to reduce cardiovascular death or worsening
heart failure (HF) events in patients with HF with mildly reduced or preserved ejection …

Importance Dapagliflozin has been shown to reduce the risk of cardiovascular death or
worsening heart failure (HF) in patients with chronic HF and reduced ejection fraction …

Background: In a post hoc analysis, the frequency of occurrence of an early decline (dip) in
estimated glomerular filtration rate (eGFR) after initiation of dapagliflozin and its association …

Background: Outcome trials in patients with type 2 diabetes mellitus have demonstrated
reduced hospitalizations for heart failure (HF) with sodium-glucose co-transporter-2 …

Background Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have been shown to
reduce the risk of incident heart failure hospitalization in individuals with type 2 diabetes …